You are here: Home » Current Affairs » Coronavirus » News
Business Standard

WHO has lifted barriers for Sputnik V approval: Russian Health Minister

Russia first applied for approval from the WHO for their vaccine in February but has not yet received an Emergency Use Listing (EUL).

World Health Organization | Russia



All obstacles preventing the certification of the Russian Sputnik V vaccine against by the (WHO) have been removed, Russian Health Minister Mikhail Murashko said at a briefing in Geneva.

"All barriers have been lifted as of today. We do not see any obstacles for continuing our work. This was confirmed by the WHO director general," Murashko said at a briefing in Geneva in response to a question by Russian News Agency TASS.

first applied for approval from the WHO for their vaccine in February but has not yet received an Emergency Use Listing (EUL).

The Russian COVID-19 vaccine Sputnik V is an adenoviral-based, two-part vaccine against the SARS-CoV-2 Produced in Russia, Sputnik V uses a weakened virus to deliver small parts of a pathogen and stimulate an immune response.

Murashko met WHO Director-General Tedros Adhanom Ghebreyesus here during which the procedure of including Sputnik V in the list of vaccines recommended by the organization for the emergency use listing for fighting the infection was discussed.

Following the meeting, the Russian health minister said: "The position of the Russian Federation on promoting and registering the Russian Sputnik V vaccine was heard. We have completely resolved all issues to date."

The efficacy of the Sputnik V vaccine is confirmed at 91.6 per cent, the results of a Phase III clinical trial of the vaccine are published in the Lancet, one of the world's oldest and most respected medical journals, as per the Russian Direct Investment Fund.

According to the analysis of data from 3.8 million vaccinated persons in Sputnik V demonstrates 97.6 per cent efficacy.

The vaccine provides 100 per cent protection against severe COVID-19.

Sputnik V vaccine is approved by 70 countries with a total population of 4 billion people - over 50 per cent of the world population. The vaccine supplies for the global market will be produced by RDIF's international partners in India, Brazil, China, South Korea and other countries.

Last month, the had suspended the approval process for Russia's Sputnik V COVID vaccine.

A regional WHO official said the manufacturing process of the jab had not met the necessary standards.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, October 02 2021. 19:00 IST